MoonLake Immunotherapeutics: directors' dealings · United States · SEC (Form 4)

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (NASDAQ: MLTX) is a clinical-stage biotechnology company based in the United States and listed on the NASDAQ market. Founded in 2021 by an international team of immunology specialists, the company has built its strategy around a single lead asset, sonelokimab (SLK), a tri-specific Nanobody® designed to target the IL-17A/IL-17F inflammatory pathway. While MoonLake’s operational headquarters are in Zug, Switzerland, it is still a U.S.-listed issuer that is closely followed by investors in growth healthcare and biotech. MoonLake’s business model is that of a development-stage company: it does not yet commercialize a product and instead focuses on clinical development, regulatory planning, and manufacturing readiness. The investment case is centered on SLK’s potential to become a differentiated therapy across inflammatory diseases with substantial unmet need, especially hidradenitis suppurativa (HS), palmoplantar pustulosis (PPP), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). Management describes the strategy as a “pipeline within a product,” meaning one molecule being advanced across multiple related indications. From a competitive standpoint, MoonLake operates in therapeutic areas where biologic treatments already exist, but where response depth, durability, tolerability, and convenience remain key differentiators. The company positions SLK as an IL-17A/F-balanced inhibitor with the potential for deep tissue penetration and strong clinical activity in both skin and joint disease. That places MoonLake in direct competition with much larger dermatology and rheumatology franchises, but with a narrow, highly focused scientific profile that could create upside if clinical execution remains strong. Recent news has materially advanced the regulatory narrative. In January 2026, MoonLake said it received positive FDA feedback on its biologics license application strategy for HS, supporting a planned BLA submission in the second half of 2026. In February 2026, the FDA granted Fast Track designation to sonelokimab in PPP, improving the development pathway for that program. The company also released updated clinical data through 2025 and early 2026 across the VELA, MIRA, LEDA, S-OLARIS and IZAR programs, creating a busy catalyst calendar. For international investors, MoonLake remains a high-risk, high-upside biotech story driven by a single lead asset, rapid clinical execution, and a heavy dependence on future regulatory milestones.